WallStreetZenWallStreetZen

NASDAQ: DNTH
Dianthus Therapeutics Inc Stock Ownership - Who owns Dianthus Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Dianthus Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Paula SoteropoulosDirector2026-05-08599$8.44
$5.06kBuy
Paula SoteropoulosDirector2026-05-08599$85.47
$51.20kSell
Ryan SavitzEVP CFO CBO2026-04-098,224$89.84
$738.84kSell
Ryan SavitzEVP CFO CBO2026-04-098,224$17.88
$147.05kBuy
Paula SoteropoulosDirector2026-03-31599$8.44
$5.06kBuy
Ryan SavitzEVP CFO CBO2026-03-317,232$85.54
$618.63kSell
Ryan SavitzEVP CFO CBO2026-03-3140,000$17.88
$715.20kBuy
Ryan SavitzEVP CFO CBO2026-03-311,390$78.33
$108.88kSell
Ryan SavitzEVP CFO CBO2026-03-3121,825$78.86
$1.72MSell
Ryan SavitzEVP CFO CBO2026-03-311,485$80.25
$119.17kSell

1 of 6

DNTH insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when DNTH insiders and whales buy or sell their stock.

DNTH Shareholders

What type of owners hold Dianthus Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fairmount Funds Management LLC14.93%8,164,219$682.53MInsider
Fmr LLC14.21%7,767,686$649.38MInstitution
Bruce Booth7.53%4,117,125$344.19MInsider
Gv 2016 GP LLC6.11%3,339,137$279.15MInsider
Blake Byers6.11%3,339,137$279.15MInsider
Blackrock Inc5.81%3,175,703$265.49MInstitution
Atlas Venture Fund X LP5.76%3,148,399$263.21MInsider
Third Rock Ventures IV LP5.59%3,058,204$255.67MInsider
Lei Meng4.97%2,717,554$227.19MInsider
Ra Capital Management LP4.78%2,611,733$218.34MInstitution

1 of 3

DNTH vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
DNTH64.81%35.19%Net BuyingNet Buying
CRSP69.13%30.87%Net BuyingNet Selling
LEGN25.97%0.15%Net SellingNet Selling
MANE62.15%15.06%Net Buying
LGND18.49%81.51%Net SellingNet Selling
View Top Biotech Stocks

Dianthus Therapeutics Stock Ownership FAQ

Who owns Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ: DNTH) is owned by 113.62% institutional shareholders, 61.70% Dianthus Therapeutics insiders, and 0.00% retail investors. Fairmount Funds Management LLC is the largest individual Dianthus Therapeutics shareholder, owning 8.16M shares representing 14.93% of the company. Fairmount Funds Management LLC's Dianthus Therapeutics shares are currently valued at $699.43M.

If you're new to stock investing, here's how to buy Dianthus Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.